SEARCH

SEARCH BY CITATION

Cited in:

CrossRef

This article has been cited by:

  1. 1
    J. Kahle, A. Orlowski, D. Stichel, J. F. Healey, E. T. Parker, S. M. Donfield, J. Astermark, E. Berntorp, P. Lollar, D. Schwabe, C. Königs, Anti-factor VIII antibodies in brothers with haemophilia A share similar characteristics, Haemophilia, 2017, 23, 2
  2. 2
    Massimo Franchini, Pier Mannuccio Mannucci, Efficacy and safety of a recombinant factor VIII produced from a human cell line (simoctocog alfa), Expert Opinion on Drug Safety, 2017, 16, 3, 405

    CrossRef

  3. 3
    Jeongheon Yoon, Anja Schmidt, Ai-Hong Zhang, Christoph Königs, Yong Chan Kim, David W. Scott, FVIII-specific human chimeric antigen receptor T-regulatory cells suppress T- and B-cell responses to FVIII, Blood, 2017, 129, 2, 238

    CrossRef

  4. 4
    Alfonso Iorio, Kathelijn Fischer, Michael Makris, Large scale studies assessing anti-factor VIII antibody development in previously untreated haemophilia A: what has been learned, what to believe and how to learn more, British Journal of Haematology, 2017, 177, 5
  5. You have free access to this content5
    Management of Inherited Bleeding Disorders in Pregnancy, BJOG: An International Journal of Obstetrics & Gynaecology, 2017, 124, 7
  6. 6
    F. Peyvandi, C. E. Ettingshausen, J. Goudemand, V. Jiménez-Yuste, E. Santagostino, M. Makris, New findings on inhibitor development: from registries to clinical studies, Haemophilia, 2017, 23,
  7. 7
    Antonino Cannavò, Carla Valsecchi, Isabella Garagiola, Roberta Palla, Pier Mannuccio Mannucci, Frits R. Rosendaal, Flora Peyvandi, Nonneutralizing antibodies against factor VIII and risk of inhibitor development in severe hemophilia A, Blood, 2017, 129, 10, 1245

    CrossRef

  8. 8
    H. M. Berg, S. Pipe, R. Ljung, Plasma products do not solve the inhibitor problem, Haemophilia, 2017, 23, 3
  9. 9
    Pier Mannuccio Mannucci, Massimo Iacobelli, Progress in the contemporary management of hemophilia: The new issue of patient aging, European Journal of Internal Medicine, 2017,

    CrossRef

  10. 10
    A. Iorio, Research and policy implications of a recently published controlled study in previously untreated haemophilia patients at high risk of inhibitor development, Haemophilia, 2017, 23, 3
  11. 11
    M. Makris, C. M. Kessler, SIPPET trial: the answers, Haemophilia, 2017, 23, 3
  12. You have free access to this content12
    F. Peyvandi, P. M. Mannucci, R. Palla, F. R. Rosendaal, SIPPET: methodology, analysis and generalizability, Haemophilia, 2017, 23, 3
  13. 13
    Lize F.D. van Vulpen, Giorgia Saccullo, Alfonso Iorio, Michael Makris, The current state of adverse event reporting in hemophilia, Expert Review of Hematology, 2017, 10, 2, 161

    CrossRef

  14. 14
    Qizhen Shi, Robert R. Montgomery, Platelets in Thrombotic and Non-Thrombotic Disorders, 2017,

    CrossRef

  15. 15
    Shamsoreza Tabriznia-Tabrizi, Marzie Gholampour, Hassan Mansouritorghabeh, A close insight to factor VIII inhibitor in the congenital hemophilia A, Expert Review of Hematology, 2016, 9, 9, 903

    CrossRef

  16. 16
    Flora Peyvandi, Pier M. Mannucci, Isabella Garagiola, Amal El-Beshlawy, Mohsen Elalfy, Vijay Ramanan, Peyman Eshghi, Suresh Hanagavadi, Ramabadran Varadarajan, Mehran Karimi, Mamta V. Manglani, Cecil Ross, Guy Young, Tulika Seth, Shashikant Apte, Dinesh M. Nayak, Elena Santagostino, Maria Elisa Mancuso, Adriana C. Sandoval Gonzalez, Johnny N. Mahlangu, Santiago Bonanad Boix, Monica Cerqueira, Nadia P. Ewing, Christoph Male, Tarek Owaidah, Veronica Soto Arellano, Nathan L. Kobrinsky, Suvankar Majumdar, Rosario Perez Garrido, Anupam Sachdeva, Mindy Simpson, Mathew Thomas, Ezio Zanon, Bulent Antmen, Kaan Kavakli, Marilyn J. Manco-Johnson, Monica Martinez, Esperanza Marzouka, Maria G. Mazzucconi, Daniela Neme, Angeles Palomo Bravo, Rogelio Paredes Aguilera, Alessandra Prezotti, Klaus Schmitt, Brian M. Wicklund, Bulent Zulfikar, Frits R. Rosendaal, A Randomized Trial of Factor VIII and Neutralizing Antibodies in Hemophilia A, New England Journal of Medicine, 2016, 374, 21, 2054

    CrossRef

  17. 17
    H. Marijke van den Berg, Different impact of factor VIII products on inhibitor development?, Thrombosis Journal, 2016, 14, S1

    CrossRef

  18. 18
    Dario Maratea, Valeria Fadda, Sabrina Trippoli, Andrea Messori, Economic analysis of not running tenders for recombinant Factor VIII procurement: a simplified analysis to estimate an otherwise unknown pharmacoeconomic index, European Journal of Hospital Pharmacy, 2016, 23, 4, 219

    CrossRef

  19. 19
    Aleksander Skotnicki, Toshko J. Lissitchkov, Vasily Mamonov, Evgeny Buevich, Kazimierz Kuliczkowski, Stefcho Goranov, Janusz Kłoczko, Anna Klukowska, Svetlana Stankovic, Liana Gercheva, Tatiana Chernova, Andrzej Hellmann, Anna Dmoszyńska, Krystyna Zawilska, Alex Veldman, Christine Joch, Wilfried Seifert, Efficacy, safety and pharmacokinetic profiles of a plasma-derived VWF/FVIII concentrate (VONCENTO®) in subjects with haemophilia A (SWIFT-HA study), Thrombosis Research, 2016, 137, 119

    CrossRef

  20. 20
    P. Mathew, H. Dinter, N. Church, T. J. Humphries, R. Kulkarni, Inhibitors in haemophilia A: a perspective on clotting factor products as a potential contributing factor, Haemophilia, 2016, 22, 3
  21. 21
    J. Goudemand, F. Peyvandi, S. Lacroix-Desmazes, Key insights to understand the immunogenicity of FVIII products, Thrombosis and Haemostasis, 2016, 116, Suppl. 1, S2

    CrossRef

  22. 22
    S. W. Pipe, R. R. Montgomery, K. P. Pratt, P. J. Lenting, D. Lillicrap, Life in the shadow of a dominant partner: the FVIII-VWF association and its clinical implications for hemophilia A, Blood, 2016, 128, 16, 2007

    CrossRef

  23. 23
    A. Schmidt, K. Brettschneider, J. Kahle, A. Orlowski, K. Becker-Peters, D. Stichel, J. Schulze, M. Braner, R. Tampé, D. Schwabe, C. Königs, Neutralisation of factor VIII inhibitors by anti-idiotypes isolated from phage-displayed libraries, Thrombosis and Haemostasis, 2016, 116, 1, 32

    CrossRef

  24. 24
    Mike Laffan, New products for the treatment of haemophilia, British Journal of Haematology, 2016, 172, 1
  25. You have free access to this content25
    Jan Astermark, Dan Hart, Sébastien Lobet, Jan Blatný, Roseline d'Oiron, Gili Kenet, Gerry Dolan, Valérie Libotte, Cedric Hermans, Partnering to change the world for people with haemophilia: 6th Haemophilia Global Summit, Prague, Czech Republic, 24–26th September 2015, European Journal of Haematology, 2016, 97,
  26. 26
    E. Berntorp, Plasma-derived versus recombinant factor concentrates in PUPs: a never ending debate?, Hämostaseologie, 2016, 37, 1, 53

    CrossRef

  27. 27
    Massimo Franchini, Giuseppe Lippi, Prevention of inhibitor development in hemophilia A in 2016. A glimpse into the future?, Thrombosis Research, 2016, 148, 96

    CrossRef

  28. 28
    P. M. Mannucci, M. E. Mancuso, M. Franchini, Tailoring hemostatic therapies to lower inhibitor development in previously untreated patients with severe hemophilia A, Journal of Thrombosis and Haemostasis, 2016, 14, 7
  29. 29
    Hiroko Izumi, Shunsuke Goto, Hideki Fujii, Kunihiko Yoshiya, Yuya Hashimura, Yoshio Katayama, Takeshi Ishimura, Masato Fujisawa, Shinichi Nishi, The case of a hemodialysis patient with hemophilia A, Nihon Toseki Igakkai Zasshi, 2016, 49, 12, 847

    CrossRef

  30. 30
    Flora Peyvandi, Isabella Garagiola, Guy Young, The past and future of haemophilia: diagnosis, treatments, and its complications, The Lancet, 2016, 388, 10040, 187

    CrossRef

  31. 31
    M. Carcao, W. Re, B. Ewenstein, The role of previously untreated patient studies in understanding the development of FVIII inhibitors, Haemophilia, 2016, 22, 1
  32. 32
    Massimo Franchini, Pier Mannuccio Mannucci, The safety of pharmacologic options for the treatment of persons with hemophilia, Expert Opinion on Drug Safety, 2016, 15, 10, 1391

    CrossRef

  33. 33
    Alanna McEneny-King, Alfonso Iorio, Gary Foster, Andrea N. Edginton, The use of pharmacokinetics in dose individualization of factor VIII in the treatment of hemophilia A, Expert Opinion on Drug Metabolism & Toxicology, 2016, 12, 11, 1313

    CrossRef

  34. 34
    Jesse Derek Lai, Maria Teofana Georgescu, Christine Hough, David Lillicrap, To clear or to fear: An innate perspective on factor VIII immunity, Cellular Immunology, 2016, 301, 82

    CrossRef

  35. 35
    Teddy Novais, Antoine Duclos, Remi Varin, Isabelle Lopez, Valérie Chamouard, Treatment-related knowledge and skills of patients with haemophilia and their informal caregivers, International Journal of Clinical Pharmacy, 2016, 38, 1, 61

    CrossRef

  36. 36
    K. Fischer, P. W. Collins, M. C. Ozelo, A. Srivastava, G. Young, V. S. Blanchette, When and how to start prophylaxis in boys with severe hemophilia without inhibitors: communication from the SSC of the ISTH, Journal of Thrombosis and Haemostasis, 2016, 14, 5
  37. 37
    Anna Klukowska, Zmiany rodzaju koncentratu czynnika krzepnięcia u chorego na hemofilię – korzyść czy ryzyko?, Acta Haematologica Polonica, 2016, 47, 2, 115

    CrossRef

  38. 38
    H. Chambost, Y. Guillaume, C. Falaise, C. Roux, F. Monpoux, Actualité sur le risque de survenue d’inhibiteur à l’initiation du traitement par concentré de facteur VIII dans l’hémophilie A sévère, Revue d'Oncologie Hématologie Pédiatrique, 2015, 3, 2, 78

    CrossRef

  39. 39
    V. Rodriguez, M. E. Mancuso, D. Warad, C. R. M. Hay, D. M. DiMichele, L. Valentino, G. Kenet, R. Kulkarni, Central venous access device (CVAD) complications in Haemophilia with inhibitors undergoing immune tolerance induction: Lessons from the international immune tolerance study, Haemophilia, 2015, 21, 5
  40. 40
    L. Miller, S. Weissmüller, E. Ringler, P. Crauwels, G. van Zandbergen, R. Seitz, Z. Waibler, Danger signal-dependent activation of human dendritic cells by plasma-derived factor VIII products, Thrombosis and Haemostasis, 2015, 114, 2, 268

    CrossRef

  41. 41
    V. Romanov, M. Marcucci, J. Cheng, L. Thabane, A. Iorio, Evaluation of safety and effectiveness of factor VIII treatment in haemophilia A patients with low titre inhibitors or a personal history of inhibitor, Thrombosis and Haemostasis, 2015, 114, 1, 56

    CrossRef

  42. 42
    J. Astermark, FVIII inhibitors: pathogenesis and avoidance, Blood, 2015, 125, 13, 2045

    CrossRef

  43. 43
    Davide Matino, Marco Gargaro, Elena Santagostino, Matteo N.D. Di Minno, Giancarlo Castaman, Massimo Morfini, Angiola Rocino, Maria E. Mancuso, Giovanni Di Minno, Antonio Coppola, Vincenzo N. Talesa, Claudia Volpi, Carmine Vacca, Ciriana Orabona, Rossana Iannitti, Maria G. Mazzucconi, Cristina Santoro, Antonella Tosti, Sara Chiappalupi, Guglielmo Sorci, Giuseppe Tagariello, Donata Belvini, Paolo Radossi, Raffaele Landolfi, Dietmar Fuchs, Louis Boon, Matteo Pirro, Emanuela Marchesini, Ursula Grohmann, Paolo Puccetti, Alfonso Iorio, Francesca Fallarino, IDO1 suppresses inhibitor development in hemophilia A treated with factor VIII, Journal of Clinical Investigation, 2015, 125, 10, 3766

    CrossRef

  44. 44
    H. M. van den Berg, S. M. Hashemi, K. Fischer, P. Petrini, R. Ljung, A. Rafowicz, M. Carcao, G. Auerswald, K. Kurnik, G. Kenet, E. Santagostino, Increased inhibitor incidence in severe haemophilia A since 1990 attributable to more low titre inhibitors, Thrombosis and Haemostasis, 2015, 115, 4, 729

    CrossRef

  45. 45
    K. Fischer, R. Lassila, F. Peyvandi, G. Calizzani, A. Gatt, T. Lambert, J. Windyga, A. Iorio, E. Gilman, M. Makris, Inhibitor development in haemophilia according to concentrate, Thrombosis and Haemostasis, 2015, 113, 5, 968

    CrossRef

  46. 46
    K. Fischer, A. Iorio, R. Lassila, F. Peyvandi, G. Calizzani, A. Gatt, T. Lambert, J. Windyga, E. A. Gilman, M. Makris, Inhibitor development in non-severe haemophilia across Europe, Thrombosis and Haemostasis, 2015, 114, 4, 670

    CrossRef

  47. 47
    M. Osooli, E. Berntorp, Inhibitors in haemophilia: what have we learned from registries? A systematic review, Journal of Internal Medicine, 2015, 277, 1
  48. 48
    A. D. Shapiro, C. Schoenig-Diesing, L. Silvati-Fidell, W. Y. Wong, V. Romanov, Integrated analysis of safety data from 12 clinical interventional studies of plasma- and albumin-free recombinant factor VIII (rAHF-PFM) in haemophilia A, Haemophilia, 2015, 21, 6
  49. 49
    Teresa Álvarez, Immaculada Soto, Jan Astermark, Non-genetic risk factors and their influence on the management of patients in the clinic, European Journal of Haematology, 2015, 94,
  50. 50
    C. Kessler, J. Oldenburg, C. Escuriola Ettingshausen, A. Tiede, K. Khair, C. Négrier, R. Klamroth, Spotlight on the human factor: building a foundation for the future of haemophilia A management, Haemophilia, 2015, 21,
  51. 51
    Oliver Tunstall, Jan Astermark, Strategies for reducing inhibitor formation in severe haemophilia, European Journal of Haematology, 2015, 94,
  52. 52
    Michelle E. Wuerth, Rebecca K. Cragerud, P. Clint Spiegel, Structure of the Human Factor VIII C2 Domain in Complex with the 3E6 Inhibitory Antibody, Scientific Reports, 2015, 5, 1

    CrossRef

  53. 53
    Elena Santagostino, Günter Auerswald, Gary Benson, Gerry Dolan, Victor Jiménez-Yuste, Thierry Lambert, Rolf Ljung, Massimo Morfini, Eduardo Remor, Silva Zupančić Šalek, Switching treatments in haemophilia: is there a risk of inhibitor development?, European Journal of Haematology, 2015, 94, 4
  54. 54
    Rolf Ljung, Nadine Gretenkort Andersson, The current status of prophylactic replacement therapy in children and adults with haemophilia, British Journal of Haematology, 2015, 169, 6
  55. 55
    C. R. M. Hay, B. P. Palmer, E. A. Chalmers, D. P. Hart, R. Liesner, S. Rangarajan, K. Talks, M. Williams, P. W. Collins, The incidence of factor VIII inhibitors in severe haemophilia A following a major switch from full-length to B-domain-deleted factor VIII: a prospective cohort comparison, Haemophilia, 2015, 21, 2
  56. 56
    A. Dunn, The long and short of it: using the new factor products, Hematology, 2015, 2015, 1, 26

    CrossRef

  57. 57
    M. Marcucci, M. E. Mancuso, E. Santagostino, G. Kenet, M. Elalfy, S. Holzhauer, C. Bidlingmaier, C. Escuriola Ettingshausen, A. Iorio, U. Nowak-Göttl, Type and intensity of FVIII exposure on inhibitor development in PUPs with haemophilia A, Thrombosis and Haemostasis, 2015, 113, 5, 958

    CrossRef

  58. 58
    D. Matino, A. Iorio, Answering relevant research questions via careful observation of clinical practice: a fresh look at the old way forward, Haemophilia, 2014, 20, 5
  59. 59
    Paola Giordano, Giuseppe Lassandro, Michele Valente, Angelo Claudio Molinari, Paola Ieranò, Antonio Coppola, Current Management of the Hemophilic Child: A Demanding Interlocutor. Quality of Life and Adequate Cost-Efficacy Analysis, Pediatric Hematology and Oncology, 2014, 31, 8, 687

    CrossRef

  60. You have free access to this content60
    H. M. Berg, Epidemiological aspects of inhibitor development redefine the clinical importance of inhibitors, Haemophilia, 2014, 20,
  61. 61
    P. W. Collins, B. P. Palmer, E. A. Chalmers, D. P. Hart, R. Liesner, S. Rangarajan, K. Talks, M. Williams, C. R. M. Hay, Factor VIII brand and the incidence of factor VIII inhibitors in previously untreated UK children with severe hemophilia A, 2000-2011, Blood, 2014, 124, 23, 3389

    CrossRef

  62. 62
    Louis Aledort, Rolf Ljung, Kenneth Mann, Steven Pipe, Factor VIII therapy for hemophilia A: current and future issues, Expert Review of Hematology, 2014, 7, 3, 373

    CrossRef

  63. 63
    A.-C. Martin, C.-M. Samama, Farmaci derivati dal plasma: frazioni coagulanti e anticoagulanti, EMC - Anestesia-Rianimazione, 2014, 19, 4, 1

    CrossRef

  64. 64
    Yoshikuni Inokawa, Hiroyuki Sugimoto, Mitsuro Kanda, Suguru Yamada, Tsutomu Fujii, Shuji Nomoto, Shin Takeda, Nobuaki Suzuki, Tadashi Matsushita, Yasuhiro Kodera, Hepatectomy for hepatocellular carcinoma in patients with hemophilia, Journal of Hepato-Biliary-Pancreatic Sciences, 2014, 21, 11
  65. 65
    C. Vézina, M. Carcao, C. Infante-Rivard, D. Lillicrap, A. M. Stain, E. Paradis, J. Teitel, G. E. Rivard, Incidence and risk factors for inhibitor development in previously untreated severe haemophilia A patients born between 2005 and 2010, Haemophilia, 2014, 20, 6
  66. 66
    Gili Kenet, Christoph Bidlingmaier, Nadja Bogdanova, Carmen Escuriola Ettingshausen, Neil Goldenberg, Sven Gutsche, Susan Halimeh, Susanne Holzhauer, Karin Kurnik, Verena Limperger, Ralf Junker, Ulrike Nowak-Göttl, Influence of factor 5 rs6025 and factor 2 rs1799963 mutation on inhibitor development in patients with hemophilia A - an Israeli-German multicenter database study, Thrombosis Research, 2014, 133, 4, 544

    CrossRef

  67. You have free access to this content67
    D. Lillicrap, K. Fijnvandraat, E. Santagostino, Inhibitors – genetic and environmental factors, Haemophilia, 2014, 20,
  68. 68
    Wolfhart Kreuz, Carmen Escuriola Ettingshausen, Inhibitors in patients with haemophilia A, Thrombosis Research, 2014, 134, S22

    CrossRef

  69. 69
    Anna Klukowska, Jak wybrać koncentrat czynnika krzepnięcia dla dziecka chorego na hemofilię?, Acta Haematologica Polonica, 2014, 45, 1, 49

    CrossRef

  70. You have free access to this content70
    J. Astermark, G. Dolan, T. Hilberg, V. Jiménez-Yuste, M. Laffan, R. Lassila, S. Lobet, C. Martinoli, C.-F. Perno, Managing Haemophilia for Life: 4th Haemophilia Global Summit, Haemophilia, 2014, 20,
  71. 71
    A.-C. Martin, C.-M. Samama, Medicamentos derivados del plasma: fracciones coagulantes y anticoagulantes, EMC - Anestesia-Reanimación, 2014, 40, 4, 1

    CrossRef

  72. 72
    M. I. Bravo, B. Da Rocha-Souto, S. Grancha, J. I. Jorquera, Native plasma-derived FVIII/VWF complex has lower sensitivity to FVIII inhibitors than the combination of isolated FVIII and VWF proteins. Impact on Bethesda assay titration of FVIII inhibitors, Haemophilia, 2014, 20, 6
  73. You have free access to this content73
    P. M. Mannucci, Q. Shi, S. Bonanad, R. Klamroth, Novel investigations on the protective role of the FVIII/VWF complex in inhibitor development, Haemophilia, 2014, 20,
  74. 74
    A. Iorio, M. Marcucci, J. Cheng, J. Oldenburg, C. Schoenig-Diesing, E. Matovinovic, V. Romanov, L. Thabane, Patient data meta-analysis of Post-Authorization Safety Surveillance (PASS) studies of haemophilia A patients treated with rAHF-PFM, Haemophilia, 2014, 20, 6
  75. 75
    T. Calvez, H. Chambost, S. Claeyssens-Donadel, R. d'Oiron, V. Goulet, B. Guillet, V. Heritier, V. Milien, C. Rothschild, V. Roussel-Robert, C. Vinciguerra, J. Goudemand, Recombinant factor VIII products and inhibitor development in previously untreated boys with severe hemophilia A, Blood, 2014, 124, 23, 3398

    CrossRef

  76. 76
    Min Xuan, Feng Xue, Rongfeng Fu, Yanhui Yang, Lei Zhang, Mengsu Tian, Renchi Yang, Retrospective analysis of 1,226 Chinese patients with haemophilia in a single medical centre, Journal of Thrombosis and Thrombolysis, 2014, 38, 1, 92

    CrossRef

  77. 77
    F. Abbonizio, A. Giampaolo, A. Coppola, R. Arcieri, H. J. Hassan, Therapeutic management and costs of severe haemophilia A patients with inhibitors in Italy, Haemophilia, 2014, 20, 4
  78. 78
    Harald Lenk, Treatment of haemophilia patients in East Germany prior to and after reunification in 1990, Thrombosis Research, 2014, 134, S57

    CrossRef

  79. 79
    Eva Zetterberg, Erik Berntorp, Contemporary Approaches to Hemophilia, 2014,

    CrossRef

  80. 80
    Massimo Franchini, Francesco Frattini, Silvia Crestani, Carlo Bonfanti, Alloantibodies in previously untreated hemophilia A patients: the role of environmental factors, Hematology, 2013, 18, 4, 183

    CrossRef

  81. 81
    Matthew S. Macauley, Fabian Pfrengle, Christoph Rademacher, Corwin M. Nycholat, Andrew J. Gale, Annette von Drygalski, James C. Paulson, Antigenic liposomes displaying CD22 ligands induce antigen-specific B cell apoptosis, Journal of Clinical Investigation, 2013, 123, 7, 3074

    CrossRef

  82. 82
    Christoph Kannicht, Margareta Ramström, Guido Kohla, Maya Tiemeyer, Elisabeth Casademunt, Olaf Walter, Helena Sandberg, Characterisation of the post-translational modifications of a novel, human cell line-derived recombinant human factor VIII, Thrombosis Research, 2013, 131, 1, 78

    CrossRef

  83. You have free access to this content83
    Peter W. Collins, Elizabeth Chalmers, Daniel P. Hart, Ri Liesner, Savita Rangarajan, Kate Talks, Mike Williams, Charles R. Hay, Diagnosis and treatment of factor VIII and IX inhibitors in congenital haemophilia: (4th edition), British Journal of Haematology, 2013, 160, 2
  84. 84
    Samantha C. Gouw, Johanna G. van der Bom, Rolf Ljung, Carmen Escuriola, Ana R. Cid, Ségolène Claeyssens-Donadel, Christel van Geet, Gili Kenet, Anne Mäkipernaa, Angelo Claudio Molinari, Wolfgang Muntean, Rainer Kobelt, George Rivard, Elena Santagostino, Angela Thomas, H. Marijke van den Berg, Factor VIII Products and Inhibitor Development in Severe Hemophilia A, New England Journal of Medicine, 2013, 368, 3, 231

    CrossRef

  85. 85
    A. Gringeri, C. Leissinger, P. A. Cortesi, H. Jo, F. Fusco, S. Riva, B. Antmen, E. Berntorp, C. Biasoli, S. Carpenter, K. Kavakli, M. Morfini, C. Négrier, A. Rocino, W. Schramm, J. Windyga, B. Zülfikar, L. G. Mantovani, Health-related quality of life in patients with haemophilia and inhibitors on prophylaxis with anti-inhibitor complex concentrate: results from the Pro-FEIBA study, Haemophilia, 2013, 19, 5
  86. 86
    Massimo Franchini, Pier Mannuccio Mannucci, Hemophilia A in the third millennium, Blood Reviews, 2013, 27, 4, 179

    CrossRef

  87. 87
    Giuseppe Tagariello, Alfonso Iorio, Davide Matino, Donata Belvini, Roberta Salviato, Roberto Sartori, Paolo Radossi, High rate of spontaneous inhibitor clearance during the long term observation study of a single cohort of 524 haemophilia A patients not undergoing immunotolerance, Journal of Hematology & Oncology, 2013, 6, 1, 63

    CrossRef

  88. 88
    Riten Kumar, Manuel Carcao, Inherited Abnormalities of Coagulation, Pediatric Clinics of North America, 2013, 60, 6, 1419

    CrossRef

  89. 89
    M. Xi, M. Makris, M. Marcucci, E. Santagostino, P. M. Mannucci, A. Iorio, Inhibitor development in previously treated hemophilia A patients: a systematic review, meta-analysis, and meta-regression, Journal of Thrombosis and Haemostasis, 2013, 11, 9
  90. 90
    R. Kruse-Jarres, Inhibitors: our greatest challenge. Can we minimize the incidence?, Haemophilia, 2013, 19,
  91. 91
    Sibylle A. Kozek-Langenecker, Arash Afshari, Pierre Albaladejo, Cesar Aldecoa Alvarez Santullano, Edoardo De Robertis, Daniela C. Filipescu, Dietmar Fries, Klaus Görlinger, Thorsten Haas, Georgina Imberger, Matthias Jacob, Marcus Lancé, Juan Llau, Sue Mallett, Jens Meier, Niels Rahe-Meyer, Charles Marc Samama, Andrew Smith, Cristina Solomon, Philippe Van der Linden, Anne Juul Wikkelsø, Patrick Wouters, Piet Wyffels, Management of severe perioperative bleeding, European Journal of Anaesthesiology, 2013, 30, 6, 270

    CrossRef

  92. 92
    S. Butenas, J. Krudysz-Amblo, G. E. Rivard, K. G Mann, Product-dependent anti-factor VIII antibodies, Haemophilia, 2013, 19, 4
  93. 93
    A. Klukowska, V. Komrska, M. Jansen, P. Laguna, Response to the Letter to the Editor by Ewenstein BM and Reininger AJ, Haemophilia, 2013, 19, 4
  94. 94
    Susan Halimeh, Christoph Bidlingmaier, Christine Heller, Sven Gutsche, Susanne Holzhauer, Gili Kenet, Karin Kurnik, Daniela Manner, Alfonso Iorio, Ulrike Nowak-Göttl, Risk Factors for High-Titer Inhibitor Development in Children with Hemophilia A: Results of a Cohort Study, BioMed Research International, 2013, 2013, 1

    CrossRef

  95. 95
    M. Franchini, C. Mengoli, RODIN and the pitfalls of observational studies, Haemophilia, 2013, 19, 5
  96. 96
    Patrick F. Fogarty, Craig M. Kessler, Consultative Hemostasis and Thrombosis, 2013,

    CrossRef

  97. 97
    B. Samor, C. Michalski, M.-P. Brandin, M.-H. Andre, S. Chtourou, Z. Tellier, A qualitative and quantitative analysis of von Willebrand factor contained in a very high-purity plasma-derived FVIII concentrate, Vox Sanguinis, 2012, 103, 1
  98. 98
    A. Iorio, P. Puccetti, M. Makris, Clotting factor concentrate switching and inhibitor development in hemophilia A, Blood, 2012, 120, 4, 720

    CrossRef

  99. 99
    A. BATOROVA, P. HOLME, A. GRINGERI, M. RICHARDS, C. HERMANS, C. ALTISENT, M. LOPEZ-FERNÁNDEZ, K. FIJNVANDRAAT, Continuous infusion in haemophilia: current practice in Europe, Haemophilia, 2012, 18, 5
  100. 100
    Massimo Franchini, Annarita Tagliaferri, Carlo Mengoli, Mario Cruciani, Cumulative inhibitor incidence in previously untreated patients with severe hemophilia A treated with plasma-derived versus recombinant factor VIII concentrates: A critical systematic review, Critical Reviews in Oncology/Hematology, 2012, 81, 1, 82

    CrossRef

  101. 101
    P. Milanov, L. Ivanciu, D. Abriss, P. Quade-Lyssy, W. Miesbach, S. Alesci, T. Tonn, M. Grez, E. Seifried, J. Schuttrumpf, Engineered factor IX variants bypass FVIII and correct hemophilia A phenotype in mice, Blood, 2012, 119, 2, 602

    CrossRef

  102. 102
    G. Auerswald, A. Thompson, M. Recht, D. Brown, R. Liesner, N. Guzman-Becerra, J. Dyck-Jones, B. Ewenstein, B. Abbuehl, Experience of Advate rAHF-PFM in previously untreated patients and minimally treated patients with haemophilia A, Thrombosis and Haemostasis, 2012, 107, 6, 1072

    CrossRef

  103. 103
    Q. SHI, E. L. KUETHER, J. A. SCHROEDER, C. L. PERRY, S. A. FAHS, J. COX GILL, R. R. MONTGOMERY, Factor VIII inhibitors: von Willebrand factor makes a difference in vitro and in vivo, Journal of Thrombosis and Haemostasis, 2012, 10, 11
  104. 104
    Helena Sandberg, Christoph Kannicht, Peter Stenlund, Marina Dadaian, Ulla Oswaldsson, Carina Cordula, Olaf Walter, Functional characteristics of the novel, human-derived recombinant FVIII protein product, human-cl rhFVIII, Thrombosis Research, 2012, 130, 5, 808

    CrossRef

  105. 105
    C. Bidlingmaier, M. Olivieri, K. Kurnik, Hautblutungen bei Kindern, Monatsschrift Kinderheilkunde, 2012, 160, 6, 538

    CrossRef

  106. You have free access to this content106
    M. MAKRIS, C. R. M. HAY, A. GRINGERI, R. D’OIRON, How I treat inhibitors in haemophilia, Haemophilia, 2012, 18,
  107. 107
    P. M. Mannucci, M. E. Mancuso, E. Santagostino, How we choose factor VIII to treat hemophilia, Blood, 2012, 119, 18, 4108

    CrossRef

  108. 108
    S. Grancha, A. M. Ortiz, C. Marañón, K. Hampel, A. Moret, B. Zimmermann, J. I. Jorquera, J. A. Aznar, Kinetics of the interaction between anti-FVIII antibodies and FVIII from therapeutic concentrates, with and without von Willebrand factor, assessed by surface plasmon resonance, Haemophilia, 2012, 18, 6
  109. 109
    Geoffrey Kershaw, Emmanuel J. Favaloro, Laboratory identification of factor inhibitors: an update, Pathology, 2012, 44, 4, 293

    CrossRef

  110. 110
    C. SILVA PINTO, T. FIDALGO, R. SALVADO, D. MARQUES, E. GONÇALVES, P. MARTINHO, A. MARKOFF, N. MARTINS, M. LETÍCIA RIBEIRO, Molecular diagnosis of haemophilia A at Centro Hospitalar de Coimbra in Portugal: study of 103 families – 15 new mutations, Haemophilia, 2012, 18, 1
  111. 111
    Massimo Franchini, Pier Mannucci, Past, present and future of hemophilia: a narrative review, Orphanet Journal of Rare Diseases, 2012, 7, 1, 24

    CrossRef

  112. You have free access to this content112
    J. ASTERMARK, Prevention and prediction of inhibitor risk, Haemophilia, 2012, 18,
  113. 113
    M. E. MANCUSO, P. M. MANNUCCI, A. ROCINO, I. GARAGIOLA, A. TAGLIAFERRI, E. SANTAGOSTINO, Source and purity of factor VIII products as risk factors for inhibitor development in patients with hemophilia A, Journal of Thrombosis and Haemostasis, 2012, 10, 5
  114. 114
    Cedric Hermans, Hans-Hermann Brackmann, Piercarla Schinco, Günter Auerswald, The case for wider use of recombinant factor VIII concentrates, Critical Reviews in Oncology/Hematology, 2012, 83, 1, 11

    CrossRef

  115. 115
    Elisabeth Casademunt, Kristina Martinelle, Mats Jernberg, Stefan Winge, Maya Tiemeyer, Lothar Biesert, Sigurd Knaub, Olaf Walter, Carola Schröder, The first recombinant human coagulation factor VIII of human origin: human cell line and manufacturing characteristics, European Journal of Haematology, 2012, 89, 2
  116. You have free access to this content116
    P. M. MANNUCCI, The role of natural VWF/FVIII complex concentrates in contemporary haemophilia care: a guideline for the next decade, Haemophilia, 2012, 18,
  117. 117
    A. SHIRAHATA, K. FUKUTAKE, S. HIGASA, J. MIMAYA, T. OKA, M. SHIMA, J. TAKAMATSU, M. TAKI, M. TANEICHI, A. YOSHIOKA, An analysis of factors affecting the incidence of inhibitor formation in patients with congenital haemophilia in Japan, Haemophilia, 2011, 17, 5
  118. 118
    L. M. ALEDORT, R. J. NAVICKIS, M. M. WILKES, Can B-domain deletion alter the immunogenicity of recombinant factor VIII? A meta-analysis of prospective clinical studies, Journal of Thrombosis and Haemostasis, 2011, 9, 11
  119. 119
    R. Kruse-Jarres, Current Controversies in the Formation and Treatment of Alloantibodies to Factor VIII in Congenital Hemophilia A, Hematology, 2011, 2011, 1, 407

    CrossRef

  120. 120
    P. M. MANNUCCI, Factor VIII inhibitors in previously treated hemophilic patients, Journal of Thrombosis and Haemostasis, 2011, 9, 11
  121. 121
    D. GREEN, Factor VIII inhibitors: a 50-year perspective, Haemophilia, 2011, 17, 6
  122. 122
    L. M. ALEDORT, Harmonization of clinical trial guidelines for assessing the risk of inhibitor development in hemophilia A treatment, Journal of Thrombosis and Haemostasis, 2011, 9, 3
  123. 123
    Akira ISHIGURO, Immune mechanisms involved in the development and eradication of anti-factor VIII alloantibodies in hemophilia, Japanese Journal of Clinical Immunology, 2011, 34, 6, 476

    CrossRef

  124. You have free access to this content124
    Massimo Franchini, Pier Mannuccio Mannucci, Inhibitors of propagation of coagulation (factors VIII, IX and XI): a review of current therapeutic practice, British Journal of Clinical Pharmacology, 2011, 72, 4
  125. 125
    P.L.F. Giangrande, Management of haemophilia, Paediatrics and Child Health, 2011, 21, 8, 344

    CrossRef

  126. 126
    Alessandro Gringeri, Myrvet Muça-Perja, Lucia Mangiafico, Sylvia von Mackensen, Pharmacotherapy of haemophilia A, Expert Opinion on Biological Therapy, 2011, 11, 8, 1039

    CrossRef

  127. 127
    T. STRAUSS, A. LUBETSKY, B. RAVID, D. BASHARI, J. LUBOSHITZ, S. LALEZARI, M. MISGAV, U. MARTINOWITZ, G. KENET, Recombinant factor concentrates may increase inhibitor development: a single centre cohort study, Haemophilia, 2011, 17, 4
  128. 128
    T. Burnouf, Recombinant plasma proteins, Vox Sanguinis, 2011, 100, 1
  129. 129
    Treatment of haemophilia: building on strength in the third millennium, Haemophilia, 2011, 17,
  130. 130
    Mindy L Simpson, Barbara A Konkle, Sarah J Nolan, Shweta Jain, Maissaa Janbain, Amina Rafique, Bypassing agent prophylaxis in people with hemophilia A or B with inhibitors, The Cochrane Library,
  131. 131
    Johanna G. van der Bom, Epidemiology of Inhibitors,
  132. 132
    Alfonso Iorio, Epidemiology of Inhibitors in Hemophilia,
  133. 133
    Jan Astermark, Genetic and Environmental Risk Factors for Factor VIII Inhibitor Development,
  134. 134
    Paul L.F. Giangrande, Products Used to Treat Hemophilia: Plasma-derived Coagulation Factor Concentrates,
  135. 135
    Yi Liu, Lingli Zhang, Cristina Santoro, Jie Song, Armando Rodriguez, Li Wang, Rituximab for treating inhibitors in children with hemophilia, The Cochrane Library,
  136. 136
    Yi Liu, Lingli Zhang, Cristina Santoro, Jie Song, Armando Rodriguez, Li Wang, Rituximab for treating inhibitors in people with inherited severe hemophilia, The Cochrane Library,